EFA’s total funding for 2022 was 1.023.846,19 EUR Euros: 90.89% was from corporate sources (unrestricted core- and project grants and honoraria for advisers) and 9.11% from non-corporate sources (membership fees and EU project grants). The highest contribution from a single source is 19,32%, amounting to the 197,786 Euros received from Chiesi Farmaceutici for the operating and the project programmes.
| Operating programme | Amount | % on category | % on total income |
| Grants | 335.000,00 | | |
| | Abbvie | 30.000,00 | 8,96% | 2,93% |
| | Astra Zeneca | 30.000,00 | 8,96% | 2,93% |
| | Boehringer Ingelheim | 30.000,00 | 8,96% | 2,93% |
| | Chiesi | 30.000,00 | 8,96% | 2,93% |
| | DBV Technologies | 30.000,00 | 8,96% | 2,93% |
| | LEO Pharma | 30.000,00 | 8,96% | 2,93% |
| | Novartis | 30.000,00 | 8,96% | 2,93% |
| | OM Vifor Pharma | 30.000,00 | 8,96% | 2,93% |
| | Pfizer | 30.000,00 | 8,96% | 2,93% |
| | Regeneron | 30.000,00 | 8,96% | 2,93% |
| | Roche | 30.000,00 | 8,96% | 2,93% |
| | Sanofi Genzyme | 30.000,00 | 8,96% | 2,93% |
| | Viatris* | 5.000,00 | 1,49% | 0,49% |
| Honoraria for Advisors | 3.750,00 | | |
| | Honoraria for advisors | 3.750,00 | | 0,37% |
| Membership fees | 14.500,00 | | |
| | Membership fees | 14.500,00 | | 1,42% |
| | | | | |
| Deferred income 2022 for 2023 EFA Core activities | -236.655,00 |
| Project programme | Amount | % on category | % on total income |
| EFA projects | 777.663,20 | | |
| | Atopic Eczema Consensus Europe – AbbVie | 65.368,75 | 8,41% | 6,38% |
| | Atopic Eczema Consensus Europe – Sanofi/Regeneron | 65.368,75 | 8,41% | 6,38% |
| | Atopic Eczema Consensus Europe – deferred income from 2021 | 26.105,77 | 3,36% | 2,55% |
| | BREATHE Coalition – Astra Zeneca | 48.431,00 | 6,23% | 4,73% |
| | BREATHE Coalition – Boehringer Ingelheim | 48.431,00 | 6,23% | 4,73% |
| | BREATHE Coalition – Chiesi | 48.431,00 | 6,23% | 4,73% |
| | BREATHE Coalition – Roche | 48.431,00 | 6,23% | 4,73% |
| | BREATHE Coalition – deferred income from 2021 | 39.712,10 | 5,11% | 3,88% |
| | Capacity Building – Astra Zeneca | 44.565,00 | 5,73% | 4,35% |
| | Capacity Building – Chiesi | 44.564,67 | 5,14% | 4,35% |
| | Capacity Building – Novartis | 40.000,00 | 5,14% | 3,91% |
| | Capacity Building Deferred income from 2021 | 4.500,00 | 0,58% | 0,44% |
| | DIG_IT 2.0 – Chiesi | 32.257,00 | 4,15% | 3,15% |
| | DIG_IT 2.0 – Roche | 32.257,00 | 4,15% | 3,15% |
| | DIG_IT 2.0 – deferred income from 2021 | 32.258,50 | 4,15% | 3,15% |
| | GUIDE Asthma – Astra Zeneca | 42.533,33 | 5,47% | 4,15% |
| | GUIDE Asthma – Chiesi | 42.533,33 | 5,47% | 4,15% |
| | GUIDE Asthma – OM Pharma** | 12.760,00 | 1,64% | 1,25% |
| | GUIDE Asthma – income deferred to 2023 | -40.570,00 | -5,22% | -3,96% |
| | European Parliament Interest Group – Sanofi/Regeneron | 33.225,00 | 4,27% | 3,25% |
| | European Parliament Interest Group – deferred income from 2021 | 66.500,00 | 8,55% | 6,50% |
| | Deferred income 2022 to EFA Projects 2023 | 88.550,00 | | |
| EU projects | 78.755,07 | | |
| | CURE | 36.048,97 | 45,77% | 3,52% |
| | 3TR | 8.333,29 | 10,58% | 0,81% |
| | Immuniverse | 4.941,21 | 6,27% | 0,48% |
| | TOLIFE | 7.811,40 | 9,92% | 0,76% |
| | SynAir-G | 21.620,20 | 27,45% | 2,11% |